Hottest Stocks (Over $10)	Hottest Stocks ($2-$10)	Biggest Losers (Over $10)	Biggest Losers ($2-$10)	Hottest Industries	Hottest Sectors	EPS / Sales Surprises
Enter Ticker Symbol:   Ticker Lookup Company Quote Company Profile Research Summary EPS Consensus Perspective Insider Transactions Price Performance

Enter any portion of the company’s name to find its corresponding ticker symbol:

Search for :

Zacks Company Profile for Humacyte, Inc. (HUMA : NSDQ)

• Company Description    Humacyte Inc. is a clinical-stage biotechnology platform company developing universally implantable bioengineered human tissue at commercial scale. Humacyte Inc., formerly known as Alpha Healthcare Acquisition Corp., is based in DURHAM, N.C. Number of Employees: 220

• Price / Volume Information    Yesterday's Closing Price: $1.47 Daily Weekly Monthly 20 Day Moving Average: 3,357,925 shares Shares Outstanding: 158.37 (millions) Market Capitalization: $232.81 (millions) Beta: 1.87 52 Week High: $6.77 52 Week Low: $1.15 Short Interest Ratio:   % Price Change % Price Change Relative to S&P 500 4 Week -21.81% -23.18% 12 Week -37.71% -43.42% Year To Date -70.89% -73.48%

• Address & Contact Information Street Address Phone / Fax Email Address Web URL 2525 EAST NORTH CAROLINA HIGHWAY 54 - DURHAM,NC 27713 USA ph: 919-313-9633 fax: - investors@humacyte.com http://www.humacyte.com

• General Corporate Information    Officers Laura E. Niklason - President and Chief Executive Officer Dale A. Sander - Chief Financial Officer and Treasurer Kathleen Sebelius - Director John Bamforth - Director Michael T. Constantino - Director Peer Information - (-) - (-) - (-) - (-) - (-) - (-) Industry / Sector / Ticker Info Analyst Coverage: No Industry Group: MED-BIOMED/GENE Sector: Medical CUSIP: 44486Q103 SIC: 2836 Fiscal Year Fiscal Year End: December Last Reported Quarter: 06/01/25 Next Expected EPS Date: 11/14/25 Share - Related Items Shares Outstanding: 158.37 Most Recent Split Date: (:1) Beta: 1.87 Market Capitalization: $232.81 (millions)

• EPS Information     • Dividend Information Analyst Coverage: No Dividend Yield: 0.00% Current Fiscal Quarter EPS Consensus Estimate: $-0.17 Indicated Annual Dividend: $0.00 Current Fiscal Year EPS Consensus Estimate: $-0.68 Payout Ratio: Number of Estimates in the Fiscal Year Consensus: 3.00 Change In Payout Ratio: Estmated Long-Term EPS Growth Rate: % Last Dividend Paid: NA - $0.00 Next EPS Report Date: 11/14/25

• Fundamental Ratios P/E Current FY Estimate: - Trailing 12 Months: - PEG Ratio: - Price Ratios Price/Book: 56.72 Price/Cash Flow: - Price / Sales: - EPS Growth vs. Year Ago Period: 11.11% vs. Previous Quarter: -140.00% Sales Growth vs. Year Ago Period: -% vs. Previous Quarter: -41.78% ROE 06/30/25 - - 03/31/25 - - 12/31/24 - - ROA 06/30/25 - -78.26 03/31/25 - -73.59 12/31/24 - -89.16 Current Ratio 06/30/25 - 2.45 03/31/25 - 3.68 12/31/24 - 2.40 Quick Ratio 06/30/25 - 1.93 03/31/25 - 3.28 12/31/24 - 2.40 Operating Margin 06/30/25 - - 03/31/25 - - 12/31/24 - - Net Margin 06/30/25 - - 03/31/25 - - 12/31/24 - - Pre-Tax Margin 06/30/25 - -7,171.27 03/31/25 - -15,022.44 12/31/24 - - Book Value 06/30/25 - 0.03 03/31/25 - 0.23 12/31/24 - -0.41 Inventory Turnover 06/30/25 - 0.08 03/31/25 - 0.07 12/31/24 - - Debt-to-Equity 06/30/25 - 2.97 03/31/25 - 0.36 12/31/24 - - Debt-to-Capital 06/30/25 - 74.80 03/31/25 - 26.27 12/31/24 - -

Powered by Zacks Investment Research ©